Intellia Therapeutics Inc sell The Goldman Sachs Group, Inc.
Start price
28.02.25
/
50%
€9.21
Target price
28.02.26
€8.65
Performance (%)
19.35%
End price
01.03.26
€10.99
Summary
This prediction ended on 01.03.26 with a price of €10.99. The prediction closed with a disappointing performance of 19.35%. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | 7.009% | 7.009% | 89.410% |
| iShares Core DAX® | 3,02 % | 2,20 % | 14,66 % |
| iShares Nasdaq 100 | 3,56 % | 1,33 % | 31,41 % |
| iShares Nikkei 225® | 6,62 % | 5,71 % | 49,42 % |
| iShares S&P 500 | 2,64 % | 1,01 % | 25,12 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "sell" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $9.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten